Piper Sandler lowered the firm’s price target on Myriad Genetics (MYGN) to $24 from $30 following quarterly results. The firm keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
- Myriad Genetics price target lowered to $20 from $30 at TD Cowen
- Myriad Genetics reports Q3 adjusted EPS 6c, consensus 2c
- Myriad Genetics comments on UnitedHealthcare’s updated policy
- UnitedHealth update ‘not the end’ for Myriad’s GeneSight, says Raymond James